Ethical Issues in Cell and Gene Therapy


The global market for cell and gene-based therapies is expected to surpass the $20 billion USD mark by 2025, with an annual growth rate of 21%. The main targets for cell – based therapies are high impact disease areas with significant incurable needs, including cancerheart diseaseneurodegenerative diseases, musculoskeletal disorders and autoimmune diseases. Gene therapies should then not be rushed to market, but companies should gather the required data about the impact of therapy in human community with the appropriate duration of follow-up to allow proper evaluation by payers. In addition, it is key to think about potential reimbursement of the techniques and also the pricing strategies, including risk sharing, as soon as the early clinical development phase


  • Ethical Issues in Stem Cell Research
  • Key Ethical Issues in Embryonic Stem Cell
  • IPR
  • Biosafety and rDNA Guidelines
  • Governing Stem Cell Therapy and Fundings

Related Conference of Ethical Issues in Cell and Gene Therapy

March 15-15, 2021

Genetics and Molecular biology

Paris, France
September 27-28, 2021

15th International Conference on Genomics & Pharmacogenomics

Vancouver, Canada
December 07-08, 2021

2nd World Congress on Cell and Structural Biology

Sydney, Australia
December 09-10, 2021

2nd International Conference on Geriatrics and Ageing

Sydney, Australia

Ethical Issues in Cell and Gene Therapy Conference Speakers

Recommended Sessions

Related Journals

Are you interested in